Table 1.

Demographic information on the two study cohorts

	Cohort 1			Cohort 2
	CON (n = 28)	PSO (n = 28)	IXE (n = 28)	CON (n = 17)	PSO (n = 17)	PC (n = 17)	CV (n = 10)
Male/Female	19/9	19/9	19/9	13/4	15/2	14/3	8/2
Age (years)	45 ± 11.6	45 ± 11.5	45 ± 11.5	62 ± 6.6	60 ± 7.1	63 ± 7.3	68 ± 14.3
BMI	24.1 ± 2.8	24.9 ± 2.8	26.1 ± 3.1	23.9 ± 2.4	24.1 ± 3.1	24.9 ± 3.9	23.3 ± 2.4
PASI	n/a	24.4 ± 8.7	0.4 ± 0.3	n/a	21.70 ± 12.2	16.87 ± 15.99	n/a

Values are reported as mean ± SD

BMI body mass index, PASI psoriasis area and severity index, CON group of healthy controls, PSO group of psoriasis patients, IXE group of ixekizumab-treated psoriasis patients, PC group of psoriasis patients with coronary heart disease, CV group of coronary heart disease patients without psoriasis